Biggest changeResearch and Development. R&D expenses are incurred in support of internal display development programs or programs funded by agencies or prime contractors of the U.S. Government and commercial partners. R&D costs include staffing, purchases of materials and laboratory supplies, circuit design costs, fabrication and packaging of display products and allocated overhead.
Biggest changeIn the fourth quarter of 2022, gross margins declined due to lower absorption of costs as we reduced production to make process changes in manufacturing the products. Research and Development. R&D expenses are incurred in support of internal display development programs or programs funded by agencies or prime contractors of the U.S. Government and commercial partners.
For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable.
For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in the contract value when they can be reliably estimated and realization is considered probable.
Industrial/Enterprise applications revenues represent customers who purchase our display products for use in headsets used for manufacturing, distribution, public safety, 3D metrology equipment and other industrial applications. Our 3D metrology customers are primarily located in Asia and they sell to Asian contract manufacturers who use the 3D metrology machines for quality control purposes.
Industrial/Enterprise applications revenues represent customers who purchase our display products for use in headsets used for manufacturing, distribution, public safety, 3D metrology equipment and other industrial applications. Our 3D metrology customers are primarily located in Asia and they sell to Asian contract manufacturers who use the 3D metrology machines for quality control purposes.
In the second quarter of 2022, we sold 1.5 million shares of common stock and 0.2 million shares of treasury stock for gross proceeds of $2.1 million (average of $1.26 per share) before deducting broker expenses paid by us of less than $0.1 million and in the third quarter of 2022, the Company sold 675,000 shares of common stock for gross proceeds of approximately $0.9 million (average of $1.27 per share) before deducting broker expenses paid by us of less than $0.1 million, pursuant to pursuant to the Current ATM Agreement.
In the second quarter of 2022, we sold 1.5 million shares of common stock and 0.2 million shares of treasury stock for gross proceeds of $2.1 million (average of $1.26 per share) before deducting broker expenses paid by us of less than $0.1 million and in the third quarter of 2022, the Company sold 675,000 shares of common stock for gross proceeds of approximately $0.9 million (average of $1.27 per share) before deducting broker expenses paid by us of less than $0.1 million, pursuant to the Current ATM Agreement.
For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipment of the product, although for some purchase orders, we may require advanced payment prior to shipment of the product. 30 To determine the proper revenue recognition method for contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation.
For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipment of the product, although for some purchase orders, we may require advanced payment prior to shipment of the product. 31 To determine the proper revenue recognition method for contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation.
Seasonality Our revenues have not followed a seasonal pattern for the past three years and we do not anticipate any seasonal trend to our revenues in 2023. Contractual Obligations Under our former CEO’s (“Dr. Fan”) employment agreement, commencing in January 2023, Dr.
Seasonality Our revenues have not followed a seasonal pattern for the past three years and we do not anticipate any seasonal trend to our revenues in 2024. Contractual Obligations Under our former CEO’s (“Dr. Fan”) employment agreement, commencing in January 2023, Dr.
If our estimate of total contract costs or our determination of whether the customer agrees that a milestone achievement is incorrect, our revenue could be overstated or understated and the profits or loss reported could be subject to adjustment. 31 For our commercial customers, the Company’s revenue is recognized when obligations under the terms of a contract with our customer are satisfied and the Company transfers control of the products or performs services, which is generally upon delivery of the product to the customer or performance of the services.
If our estimate of total contract costs or our determination of whether the customer agrees that a milestone achievement is incorrect, our revenue could be overstated or understated and the profits or loss reported could be subject to adjustment. 32 For our commercial customers, the Company’s revenue is recognized when obligations under the terms of a contract with our customer are satisfied and the Company transfers control of the products or performs services, which is generally upon delivery of the product to the customer or performance of the services.
Other income is primarily composed of interest income, revaluation and impairment of equity investments, foreign currency transactions, remeasurement gains and losses incurred by our UK-based subsidiaries and other non-operating income items.
Non-operating (expense) income is primarily composed of interest income, revaluation and impairment of equity investments, foreign currency transactions, remeasurement gains and losses incurred by our UK-based subsidiaries and other non-operating income items.
Historically, we have periodically recorded other-than-temporary impairment losses, however we have not done so recently. 32 Income Taxes We have historically incurred domestic operating losses from both a financial reporting and tax return standpoint. We establish valuation allowances to the extent it appears more likely than not that our deferred tax assets will not be realized.
Historically, we have periodically recorded other-than-temporary impairment losses, however we have not done so recently. 33 Income Taxes We have historically incurred domestic operating losses from both a financial reporting and tax return standpoint. We establish valuation allowances to the extent it appears more likely than not that our deferred tax assets will not be realized.
Fiscal Year 2021 Compared to Fiscal Year 2020 The provision for income taxes for the fiscal years ended 2021 and 2020 of approximately $(0.1) million was due to the accretion of additional potential liabilities related to uncertain tax positions and deferred tax liabilities for the Company’s former Korean subsidiary. Net loss (income) attributable to noncontrolling interest.
Fiscal Year 2022 Compared to Fiscal Year 2021 The provision for income taxes for the fiscal years ended 2022 and 2021 of approximately $(0.1) million was due to the accretion of additional potential liabilities related to uncertain tax positions and deferred tax liabilities for the Company’s former Korean subsidiary. Net loss attributable to noncontrolling interest.
Internal R&D expense for 2021 increased as compared to the prior year primarily due to increased OLED development. Selling, General and Administrative. Selling, general and administrative (“SG&A”) expenses consist of the expenses incurred by our sales and marketing personnel and related expenses, and administrative and general corporate expenses.
Internal R&D expense for 2022 increased as compared to the prior year primarily due to increased OLED development. Selling, General and Administrative. Selling, general and administrative (“SG&A”) expenses consist of the expenses incurred by our sales and marketing personnel and related expenses, and administrative and general corporate expenses.
We estimate we will have sufficient liquidity to fund operations at least through the first quarter of 2024. Nonetheless, we monitor the capital markets on an ongoing basis and may consider raising capital if favorable market conditions develop.
We estimate we will have sufficient liquidity to fund operations at least through the first quarter of 2025. Nonetheless, we monitor the capital markets on an ongoing basis and may consider raising capital if favorable market conditions develop.
Foreign currency translation impact on our results, if material, is described in further detail under “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” section below. 34 Fiscal Year 2021 Compared to Fiscal Year 2020 Sales of our products for Defense applications include systems used by the military both in the field and for training and simulation.
Foreign currency translation impact on our results, if material, is described in further detail under “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” section below. 35 Fiscal Year 2022 Compared to Fiscal Year 2021 Sales of our products for Defense applications include systems used by the military both in the field and for training and simulation.
Our international sales are primarily denominated in U.S. dollars. Consequently, a strengthening of the U.S. dollar could increase the price in local currencies of our products in foreign markets and make our products relatively more expensive than competitors’ products that are denominated in local currencies, which could result in a reduction in sales or profitability in those foreign markets.
Consequently, a strengthening of the U.S. dollar could increase the price in local currencies of our products in foreign markets and make our products relatively more expensive than competitors’ products that are denominated in local currencies, which could result in a reduction in sales or profitability in those foreign markets.
We have recorded deferred tax liabilities for any additional withholding tax that may be due to the Korean government upon Kowon’s final tax return acceptance. 39 We have incurred net losses of $19.3 million, $13.4 million and $4.4 million for the fiscal years 2022, 2021 and 2020, respectively, and net cash outflows from operations of $17.7 million, $10.7 million and $4.4 million for the fiscal years ended 2022, 2021 and 2020, respectively.
We have recorded deferred tax liabilities for any additional withholding tax that may be due to the Korean government upon Kowon’s final tax return acceptance. 40 We have incurred net losses of $19.7 million, $19.3 million and $13.4 million for the fiscal years 2023, 2022 and 2021, respectively, and net cash outflows from operations of $15.3 million, $17.7 million and $10.7 million for the fiscal years ended 2023, 2022 and 2021, respectively.
Because our fiscal year ends on the last Saturday of December, every seven years we have a fiscal year with 53 weeks. Our fiscal year 2022 was a 53-week year and 2021 and 2020 were 52-week years. Revenues.
Because our fiscal year ends on the last Saturday of December, every seven years we have a fiscal year with 53 weeks. Our fiscal year 2023 was a 52-week year, 2022 was a 53-week year and 2021 was a 52-week year. Revenues.
The decrease in license and royalty revenue in 2021 compared to 2020 is due to lower royalties earned under IP license agreements for industrial wearable headsets. International product sales represented approximately 38% and 20% of product revenues for 2021 and 2020, respectively.
The decrease in license and royalty revenue in 2022 compared to 2021 is due to lower royalties earned under IP license agreements for industrial wearable headsets. International product sales represented approximately 22% and 38% of product revenues for 2022 and 2021, respectively.
Tax provision (In thousands) 2022 2021 2020 Tax provision $ (144 ) $ (129 ) $ (129 ) Fiscal Year 2022 Compared to Fiscal Year 2021 The provision for income taxes for the fiscal years ended 2022 and 2021 of approximately $(0.1) million was due to the accretion of additional potential liabilities related to uncertain tax positions and deferred tax liabilities for the Company’s former Korean subsidiary.
Tax provision (In thousands) 2023 2022 2021 Tax provision $ (156 ) $ (144 ) $ (129 ) Fiscal Year 2023 Compared to Fiscal Year 2022 The provision for income taxes for the fiscal years ended 2023 and 2022 of approximately $(0.2) million and $(0.1) million, respectively, was due to the accretion of additional potential liabilities related to uncertain tax positions and deferred tax liabilities for the Company’s former Korean subsidiary.
Internal R&D expense for 2022 increased as compared to the prior year primarily due to increased OLED development. 36 Fiscal Year 2021 Compared to Fiscal Year 2020 Funded R&D expense for 2021 increased as compared to 2020 primarily due to an increase in the number of defense related contracts we have been awarded.
Internal R&D expense for 2023 decreased as compared to the prior year primarily due to decreased OLED development. 37 Fiscal Year 2022 Compared to Fiscal Year 2021 Funded R&D expense for 2022 increased as compared to 2021 primarily due to an increase in the number of defense related contracts we have been awarded.
Predicting our R&D revenue and related trends is challenging because we have limited ability to forecast whether we will be awarded additional R&D contracts in the future as such awards depend on the U.S. military budget and priorities.
Accordingly, there can be no assurances we will continue to ship under our defense contracts. 34 Predicting our R&D revenue and related trends is challenging because we have limited ability to forecast whether we will be awarded additional R&D contracts in the future as such awards depend on the U.S. military budget and priorities.
Our revenues by display application, which include product sales and amounts earned from research and development contracts, for fiscal years 2022, 2021 and 2020 by category, were as follows: (In thousands) 2022 2021 2020 Defense $ 24,780 $ 18,180 $ 20,231 Industrial/Enterprise 6,136 9,710 6,882 Consumer 1,497 1,871 852 Research and Development 14,357 14,669 10,123 Other 7 121 553 License and royalties 624 1,115 1,487 Total Revenues $ 47,401 $ 45,666 $ 40,128 Fiscal Year 2022 Compared to Fiscal Year 2021 Sales of our products for Defense applications include systems used by the military both in the field and for training and simulation.
Our revenues by display application, which include product sales and amounts earned from research and development contracts, for fiscal years 2023, 2022 and 2021 by category, were as follows: (In thousands) 2023 2022 2021 Defense $ 22,615 $ 24,780 $ 18,180 Industrial/Enterprise 2,736 6,136 9,710 Consumer 573 1,497 1,871 Research and Development 13,455 14,357 14,669 Other 13 7 121 License and royalties 1,002 624 1,115 Total Revenues $ 40,394 $ 47,401 $ 45,666 Fiscal Year 2023 Compared to Fiscal Year 2022 Sales of our products for Defense applications include systems used by the military both in the field and for training and simulation.
For example, if the customer is located in Asia or if a U.S. customer has its Asian contract manufacturer order product from us and we deliver the product to Asia, we categorize both these sales as international.
We categorize our revenues as either domestic or international based upon the delivery destination of our product. For example, if the customer is located in Asia or if a U.S. customer has its Asian contract manufacturer order product from us and we deliver the product to Asia, we categorize both these sales as international.
The increase in Industrial/Enterprise applications revenues in 2021 compared to 2020 was primarily due to an increase in sales to customers who use our display components in 3D metrology equipment and industrial headsets. Sales of our displays for Consumer applications is primarily for the use in thermal imaging products, recreational rifle and hand-held scopes.
The decrease in Industrial/Enterprise applications revenues in 2023 compared to 2022 was primarily due to a decrease in sales to customers who use our display components in 3D metrology equipment and industrial headsets. Sales of our displays for Consumer applications are primarily for use in thermal imaging products, recreational rifle and hand-held scopes.
These contracts typically reimburse us for direct costs and allocated overhead and selling, general and administrative costs and in some cases profit. In 2021 and 2020 our R&D revenues exceeded funded R&D expenses by approximately $4.7 million and $2.4 million, respectively.
These contracts typically reimburse us for direct costs and allocated overhead and selling, general and administrative costs and in some cases profit. In 2023 and 2022, our R&D revenues exceeded funded R&D expenses by approximately $6.3 million and $4.1 million, respectively.
SG&A expenses for the fiscal years 2022, 2021 and 2020 were as follows: (In thousands, except percentages) 2022 2021 2020 Selling, general and administrative expense $ 17,965 $ 18,101 $ 11,823 Selling, general and administrative expense as a % of total revenue 37.9 % 39.6 % 29.5 % Fiscal Year 2022 Compared to Fiscal Year 2021 SG&A for 2022 decreased as compared to 2021 primarily due to a decrease of approximately $2.9 million in non-cash stock-based compensation, partially offset by a $0.8 million increase in compensation and benefits and $1.4 million of higher professional fees.
SG&A expenses for the fiscal years 2023, 2022 and 2021 were as follows: (In thousands, except percentages) 2023 2022 2021 Selling, general and administrative expense $ 21,842 $ 17,965 $ 18,101 Selling, general and administrative expense as a % of total revenue 54.1 % 37.9 % 39.6 % Fiscal Year 2023 Compared to Fiscal Year 2022 SG&A for 2023 increased as compared to 2022 primarily due to an increase of approximately $5.0 million in legal and professional fees and $1.0 million in non-cash stock-based compensation, partially offset by a $1.3 million decrease in compensation and benefits.
Our OLED displays are designed by us and manufactured by third parties for us. We are a display supplier for the U.S. Army’s Family of Weapon Sights-Individual and Joint Strike Fighter F-35 programs and are undergoing qualification for the FWS - Crew Served variant.
FDD, our wholly-owned subsidiary, manufactures our LCOS microdisplays in its facility located in Scotland. Our OLED displays are designed by us and manufactured by third parties for us. We are a display supplier for the U.S. Army’s Family of Weapon Sights-Individual and Joint Strike Fighter F-35 programs and are undergoing qualification for the FWS - Crew Served variant.
In 2022 we recorded a $2.0 million impairment charge on an equity investment. Also in 2022, we recorded $0.3 million of foreign currency losses compared to $0.1 million of foreign currency gains recorded in 2021.
Fiscal Year 2022 Compared to Fiscal Year 2021 In 2022 we recorded a gain of $4.7 million resulting from the revaluation of an equity investment. In 2022 we recorded a $2.0 million impairment charge on an equity investment. Also in 2022, we recorded $0.3 million of foreign currency losses compared to $0.1 million of foreign currency gains recorded in 2021.
The inability to procure a single component will prevent the completion of our product and the ability to sell the product. Our products go through extensive qualification processes and therefore our customers may not accept a replacement component. We are unable to determine if we will be able to obtain all necessary components for fiscal 2023.
Our products go through extensive qualification processes and therefore our customers may not accept a replacement component. We are unable to determine if we will be able to obtain all necessary components for fiscal 2024.
As of December 31, 2022, we owned 80% of the equity of eMDT. Net loss (income) attributable to noncontrolling interest on our consolidated statement of operations represents the portion of the results of operations of our majority owned subsidiaries which is allocated to the shareholders of the equity interests not owned by us.
In the first quarter of 2023, we acquired the remaining interest in eMDT. Net loss attributable to noncontrolling interest on our consolidated statement of operations represents the portion of the results of operations of our majority owned subsidiaries which is allocated to the shareholders of the equity interests not owned by us.
R&D revenues consist primarily of development contracts with agencies or prime contractors of the U.S. Government and commercial enterprises. We manufacture transmissive and reflective microdisplays. Our commercial and defense transmissive display production is being performed entirely in our Westborough, Massachusetts facility. FDD, our wholly-owned subsidiary, manufactures our reflective microdisplays in its facility located in Scotland.
R&D revenues consist primarily of development contracts with agencies or prime contractors of the U.S. Government and commercial enterprises. We manufacture Active-matrix Liquid Crystal (“AMLCD”) transmissive and Liquid Crystal on Silicon (“LCOS”) reflective microdisplays. Our AMLCD display production is being performed entirely in our Westborough, Massachusetts facility.
Cost of product revenues, which is comprised of materials, labor and manufacturing overhead related to the production of our products for fiscal years 2022, 2021 and 2020 were as follows: (In thousands, except percentages) 2022 2021 2020 Cost of product revenue $ 32,559 $ 25,052 $ 21,398 Cost of product revenues as a % of net product revenues 100 % 83.8 % 75.0 % Fiscal Year 2022 Compared to Fiscal Year 2021 Cost of product revenues increased as a percentage of revenues in 2022 as compared to 2021 primarily due to lower production volumes in the second and third quarters of fiscal year 2022.
Cost of product revenues, which is comprised of materials, labor and manufacturing overhead related to the production of our products for fiscal years 2023, 2022 and 2021 were as follows: (In thousands, except percentages) 2023 2022 2021 Cost of product revenues $ 24,952 $ 32,559 $ 25,052 Cost of product revenues as a % of net product revenues 96.2 % 100 % 83.8 % Fiscal Year 2023 Compared to Fiscal Year 2022 Cost of product revenues decreased as a percentage of revenues in 2023 as compared to 2022 primarily due to increased sales of higher margin products for defense applications in 2023 versus 2022 and lower sales of lower margin products from defense applications in 2023 versus 2022.
R&D expenses for fiscal years 2022, 2021 and 2020 were as follows: (In thousands) 2022 2021 2020 Funded $ 10,280 $ 9,976 $ 7,746 Internal 8,388 6,312 3,924 Total $ 18,668 $ 16,288 $ 11,670 Fiscal Year 2022 Compared to Fiscal Year 2021 Funded R&D expense for 2022 increased as compared to 2021 primarily due to an increase in the number of defense related contracts we have been awarded.
R&D expenses for fiscal years 2023, 2022 and 2021 were as follows: (In thousands) 2023 2022 2021 Funded $ 7,177 $ 10,280 $ 9,976 Internal 3,600 8,388 6,312 Total $ 10,777 $ 18,668 $ 16,288 Fiscal Year 2023 Compared to Fiscal Year 2022 Funded R&D expense for 2023 decreased as compared to 2022 primarily due to the completion of contracts for defense programs awarded prior to 2023.
The following table presents the components of our cash and cash equivalents and marketable debt securities held in U.S. dollars as of the dates presented: December 31, 2022 December 25, 2021 Domestic locations $ 11,778,324 $ 27,031,695 Foreign locations 629,793 865,416 Subtotal cash and cash equivalents and marketable debt securities held in U.S. dollars 12,408,117 27,897,111 Cash and cash equivalents held in other currencies and converted to U.S. dollars 239,539 1,398,355 Total cash and cash equivalents and marketable debt securities $ 12,647,656 $ 29,295,466 We have no plans to repatriate the cash and cash equivalents held in our foreign subsidiary FDD.
The following table presents the components of our cash, cash equivalents, restricted cash and marketable debt securities held in U.S. dollars as of the dates presented: December 30, 2023 December 31, 2022 Domestic locations $ 17,725,979 $ 11,778,324 Foreign locations 95,547 629,793 Subtotal cash, cash equivalents, restricted cash and marketable debt securities held in U.S. dollars 17,821,526 12,408,117 Cash and cash equivalents held in other currencies and converted to U.S. dollars 81,159 239,539 Total cash, cash equivalents, restricted cash and marketable debt securities $ 17,902,685 $ 12,647,656 We have no plans to repatriate the cash and cash equivalents held in our foreign subsidiary FDD.
The change in net loss attributable to noncontrolling interest in 2022 compared to 2021 was $0.1 million and in 2021 compared to 2020 was $0.1 million and was a result of net losses attributable to minority shareholders of eMDT. 38 Liquidity and Capital Resources At December 31, 2022 and December 25, 2021, we had cash and cash equivalents and marketable securities of $12.6 million and working capital of $16.4 million compared to $29.3 million and $34.7 million, respectively.
The change in net loss attributable to noncontrolling interest in 2023 compared to 2022 was less than $0.1 million and in 2022 compared to 2021 was less than $0.1 million and was the result of operations of eMDT. 39 Liquidity and Capital Resources At December 30, 2023 and December 31, 2022, we had cash and cash equivalents, including restricted cash, and marketable securities of $17.9 million and working capital of $24.0 million compared to $12.6 million and $16.4 million, respectively.
In addition, if we earn royalties on sales from a customer, the royalties are categorized as domestic or international based on how the product revenues are categorized. Our international sales decreased in 2022 as compared to 2021 due to a decrease in sales of our products for 3D metrology application by our subsidiary, FDD and industrial headset products manufactured overseas.
Our international sales decreased in 2022 as compared to 2021 due to a decrease in sales of our products for 3D metrology application by our subsidiary, FDD and industrial headset products manufactured overseas. 36 Cost of Product Revenues.
In fiscal year 2022, our Funded R&D expenditures were primarily related to our display products and defense systems and our Internal R&D was primarily related to the development of OLED displays.
R&D costs include staffing, purchases of materials and laboratory supplies, circuit design costs, fabrication and packaging of display products and allocated overhead. In fiscal year 2023, our Funded R&D expenditures were primarily related to our display products and defense systems and our Internal R&D was primarily related to the development of OLED displays.
The decrease in license and royalty revenue in 2022 compared to 2021 is due to lower royalties earned under IP license agreements for industrial wearable headsets. International product sales represented approximately 22% and 38% of product revenues for 2022 and 2021, respectively. We categorize our revenues as either domestic or international based upon the delivery destination of our product.
The increase in license and royalty revenue in 2023 compared to 2022 is due to an increase in royalties earned under IP license agreements for industrial wearable headsets. International product sales represented approximately 13% and 22% of product revenues for 2023 and 2022, respectively.
Fiscal Year 2021 Compared to Fiscal Year 2020 SG&A for 2021 increased as compared to 2020 primarily due to increases of approximately $3.1 million in non-cash stock-based compensation, $1.4 million in compensation and benefits, $0.3 million in insurance and $0.9 million in bad debt expense, partially offset by $0.6 million of lower professional fees. Impairment of Goodwill and Intangibles.
Fiscal Year 2022 Compared to Fiscal Year 2021 SG&A for 2022 decreased as compared to 2021 primarily due to a decrease of approximately $2.9 million in non-cash stock-based compensation, partially offset by a $0.8 million increase in compensation and benefits and $1.4 million of higher professional fees. 38 Total Non-operating (Expense) Income.
For fiscal year 2022 we have identified a shortage of several semiconductor components from our normal vendors which are necessary to manufacture our products. We continue to search for and procure all necessary components from our current vendors and new alternative vendors. In certain situations, we can obtain the components but at a significantly increased cost.
We continue to search for and procure all necessary components from our current vendors and new alternative vendors. In certain situations, we can obtain the components but at a significantly increased cost. The inability to procure a single component will prevent the completion of our product and the ability to sell the product.
Fan (or in the event of his death prior to completion of all installments to his surviving spouse, or if none to his estate) will receive $1,500,000 in equal monthly installments.
Fan (or in the event of his death prior to completion of all installments to his surviving spouse, or if none to his estate) would receive $1,500,000 in twenty-four (24) equal monthly installments. As of December 30, 2023, we owed Dr. Fan $750,000 which will be paid in equal monthly installments during 2024. In addition, under Dr.
The gross proceeds of these transactions were $22.9 million, before deducting underwriting discounts and offering expenses paid by us of $1.5 million.
The gross proceeds of these transactions were $22.9 million, before deducting underwriting discounts and offering expenses paid by us of $1.5 million. At December 30, 2023, we had available $41.4 million for sale of common stock under the Current ATM Agreement.
Fiscal Year 2021 Compared to Fiscal Year 2020 Cost of product revenues increased as a percentage of revenues in 2021 as compared to 2020 primarily due to lower production volumes in the second and third quarter of fiscal year 2021, which resulted from reduced production of our FWS-I products as we made some process changes in manufacturing the products.
Fiscal Year 2022 Compared to Fiscal Year 2021 Cost of product revenues increased as a percentage of revenues in 2022 as compared to 2021 primarily due to lower production volumes in the second and third quarters of fiscal year 2022.
We are also in development for a new series of displays systems for the System Enhancement Package (SEP IV) program. The FWS, SEP IV and our existing production avionic programs are expected to increase production for the next several years.
We are also in development for new display systems for armored vehicles and a medical headset for surgeons. Our existing and new production programs are expected to increase production for the next several years.
The net proceeds from the sale of common shares were used for general corporate purposes, including working capital. At December 31, 2022 we had available $41.4 million for sale of common stock under the Current ATM Agreement.
The net proceeds from the sale of common shares were used for general corporate purposes, including working capital.
Other income, for the fiscal years 2022, 2021 and 2020 were as follows: (In thousands) 2022 2021 2020 Total other income , net $ 2,608 $ 436 $ 361 Fiscal Year 2022 Compared to Fiscal Year 2021 In 2022 we recorded a gain of $4.7 million resulting from the revaluation of an equity investment.
Non-operating (expense) income for the fiscal years 2023, 2022 and 2021 were as follows: (In thousands) 2023 2022 2021 Total non-operating (expense) income $ (2,415 ) $ 2,608 $ 436 Fiscal Year 2023 Compared to Fiscal Year 2022 In 2023, we recorded $3.3 million of impairment losses on equity investments.
The following is a summary of our contractual lease payment obligations as of December 31, 2022: Payment due by period Total Less than 1 year 1-3 Years 4-5 years More than 5 years Operating Lease Obligations $ 3,914,894 976,329 2,133,232 805,333 — 40
Fan’s employment agreement he receives $40,000 per year through 2033. The following is a summary of our contractual lease payment obligations as of December 30, 2023: Payment due by period Total Less than 1 year 1-3 Years 4-5 years More than 5 years Operating Lease Obligations $ 2,844,590 795,884 1,847,373 201,333 — 41
Fiscal Year 2021 Compared to Fiscal Year 2020 In 2021, we recorded $0.1 million of foreign currency gains compared to $0.3 million of foreign currency gains recorded in 2020. In 2021, we recorded a $0.3 million gain on an equity investment.
In 2022, we recorded a gain of $4.7 million resulting from the revaluation of an equity investment. Also in 2022, we recorded a $2.0 million impairment charge on an equity investment. In 2023, we recorded $0.2 million of foreign currency losses compared to $0.3 million of foreign currency losses recorded in 2022.
Sales of our products for Defense applications may be for a one-time purchase order or for programs that run for several years. Revenues from product sales to defense customers decreased in 2021 compared to 2020, primarily due to a decrease in shipments of our products into the Joint Strike Fighter program and training and simulation programs.
Revenues from product sales to defense customers decreased in 2023 compared to 2022, primarily due to a decrease in shipments of our products for thermal weapon sight applications that was partially offset by an increase in sales of our products for defense pilot helmets and training and simulation programs.
The increase in Consumer applications in 2021 compared to 2020 was primarily due to increased demand for our OLEDs. R&D revenues increased in 2021 as compared to 2020 primarily due to additional funding for new display technology development which we believe will be used in U.S. defense programs.
R&D revenues decreased in 2023 as compared to 2022 primarily due to decreased funding for new display technology development for U.S. defense programs and OLED display development, which was partially offset by increased funding for armor vehicle targeting system and medical headset development.
Our international sales increased in 2021 as compared to 2020 due to an increase in sales of our products for 3D metrology application by our subsidiary, FDD, located in Scotland. 35 Cost of Product Revenues.
Our international sales decreased in 2023 as compared to 2022 due to a decrease in sales of our products for 3D metrology application by our subsidiary, FDD, our OLED displays for consumer applications and industrial headset products manufactured overseas. Our international sales are primarily denominated in U.S. dollars.
The change in cash and cash equivalents and marketable securities was primarily due to cash used in operations of $17.7 million, which was partially offset by cash generated from sales of our common stock.
The change in cash and cash equivalents and marketable securities was primarily due to gross proceeds of $22.9 million received from the sale of 17,000,000 shares of common stock and the pre-funded warrants to purchase up to 6,000,000 shares of common stock at a public offering price of $0.99 per share.
Our products enable our customers to develop and market an improved generation of products for these target applications. Critical Accounting Estimates Management’s discussion and analysis of our financial condition and results of operations are based upon our audited consolidated financial statements.
We believe that the technologies we are developing may eventually be used in consumer augmented reality (“AR”) and virtual reality (“VR”) wearable headsets systems. Our products are primarily used to overlay digital information on the real-world scene. Critical Accounting Estimates Management’s discussion and analysis of our financial condition and results of operations are based upon our audited consolidated financial statements.